about
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaLithium for schizophreniaBenzodiazepines for schizophreniaRisperidone versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaRisperidone versus placebo for schizophreniaValproate for schizophreniaHaloperidol versus chlorpromazine for schizophreniaTestosterone for schizophreniaLithium for schizophreniaTestosterone for schizophreniaRisperidone versus olanzapine for schizophreniaHaloperidol versus chlorpromazine for schizophreniaOlanzapine alone or in combination for acute maniaDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.A Systematic Review and Meta-Analysis Estimating the Expected Dropout Rates in Randomized Controlled Trials on Yoga InterventionsRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesSPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsAddressing missing outcome data in meta-analysis.Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis.Reporting and handling missing outcome data in mental health: a systematic review of Cochrane systematic reviews and meta-analyses.Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts.A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medicationsThe association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data.Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches.Modern antipsychotic drugs: a critical overviewA systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.Valproate for schizophrenia.Methodological issues in current antipsychotic drug trials.Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trialSafety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management.Risk:benefit assessment of old medicines.The impact of European regulatory policies on psychotropic drug prescribing patterns.A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.Volunteer bias in recruitment, retention, and blood sample donation in a randomised controlled trial involving mothers and their children at six months and two years: a longitudinal analysis.Overview of the findings from the European SOHO study.Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresImpact of referral source and study applicants' preference for randomly assigned service on research enrollment, service engagement, and evaluative outcomes.Preference in random assignment: implications for the interpretation of randomized trialsStructural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.
P2860
Q21260279-BBB5C347-28C3-41E9-B4E5-1C53C35108E7Q24186325-AB01FEDA-D638-4427-8DCF-A25199B9FB02Q24197501-4F0F2354-121C-4366-BD78-2C2F491B8853Q24234950-D5E2F618-A596-4AD6-92CA-2B7234DC2649Q24236545-D5D4D8F8-2FE7-4231-AFA0-7C2A6C5588CAQ24241041-4BE71D3D-B4B2-4308-9F1E-2812A6A6B69DQ24242157-20C06208-7F1F-41BB-9904-42C43490B1B8Q24242553-88071D83-D902-45C6-8CCA-5AC985F4C53BQ24243894-1623D820-5735-402B-9CBB-831EEBB93A50Q24244034-65F46598-2C7E-46DD-8A36-45D4B2F9F438Q24244475-E907AB87-9359-44BC-AF64-32DE258EB41EQ24246232-CD5A7199-03DA-4FE0-8B7C-3391349D4979Q24248139-0A9E765A-59BE-407E-B20E-8B8B75492625Q24250164-6B6BC3F5-2203-48F9-A7B0-6E0C7D95051FQ25257471-C78CE9F3-CF80-4C79-B127-C9D2CABB50CDQ26740420-93224367-15F3-4CD3-86B2-770E67BBB178Q26863435-B4630047-5CB8-4D7B-9E68-2DAFDFA199A4Q28710019-105F85FD-C7E8-49A2-80DF-39AD44CD5A43Q30835835-8C40EE71-76DA-42E8-944A-078C747AEDBDQ30869343-9ED0F1B4-EA42-4C3D-BED0-D9378A0E2A1AQ30976019-0F679055-EC77-41F9-A0EE-F17FA37BEE10Q30986822-11610F3B-D291-4343-87FC-30615D2E842FQ31131634-46205E1A-A6D9-46B4-A617-47E468D719EAQ31143463-124CCDBB-075C-4693-A20D-51C12BBC8BB1Q33533853-F5287675-02E0-4E50-B4BE-B8940E44A5D6Q33853390-9792293D-E88D-4401-8B31-DAD44963262EQ34224372-DBB2073F-3A11-4AFE-9BD0-41BA1C50ACA0Q34545761-4BD59028-7C82-4203-987C-23FBA0DC05B4Q34587745-9CEBDD35-3AAC-4C07-9E37-003F29F25D25Q34785866-8015BC60-3F6E-4B2A-B0AB-EFCE6B33A803Q35618441-CD39417D-365A-439D-B3F7-0D530870A99FQ35826523-E37D8FD1-4215-49FA-BA99-D894516A31EDQ36272515-B8D2E5BE-EEC8-44D1-AC26-438ADA98C641Q36573892-10BFD5D0-4D3A-4596-916B-34A36668D4BFQ36996957-AD85089F-B03D-44D6-8683-468F467C2DCCQ37174029-9DF0043B-5364-4BFA-A040-195D4A22B68AQ37227479-8C821CBD-2BA1-4341-A798-AC0100AB86B0Q37382358-7DA1C92B-ABCF-4EBC-AD7B-012193B4D6D3Q37484869-6A977EFA-F5B7-46E3-8737-ACEE7181DA32Q37886138-F1645075-DBA6-4406-9BA9-4658AACBCB36
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Dropout rates in randomised antipsychotic drug trials.
@ast
Dropout rates in randomised antipsychotic drug trials.
@en
type
label
Dropout rates in randomised antipsychotic drug trials.
@ast
Dropout rates in randomised antipsychotic drug trials.
@en
prefLabel
Dropout rates in randomised antipsychotic drug trials.
@ast
Dropout rates in randomised antipsychotic drug trials.
@en
P2093
P356
P1433
P1476
Dropout rates in randomised antipsychotic drug trials.
@en
P2093
P2888
P304
P356
10.1007/S002130100711
P577
2001-05-01T00:00:00Z
P5875
P6179
1019223610